Stephen Blyth

Stephen Blyth, CEO - Xpediator (XPD)


Stephen qualified as a Chartered Accountant in 1981.He was appointed as the MD of Bleckmann (UK) Frans Maas, a listed Dutch logistics and freight forwarding company, in 1984. He set up Delamode in the UK in 1988. Stephen also has experience across a broad range of business activities including menswear shops, safe servicing company, garment production and commercial property development.

Jon Bridges

Jon Bridges, CEO - Velocity Composites (VEL)


Jon co-founded Velocity in October 2007 and has over 25 years’ experience within the advanced composites industry and is an experienced composite engineer. Previously, Jon was an Aerospace Specialist in the materials supply chain and prior to this held various engineering, development and manufacturing roles for OEM and Tier 1 aerospace manufacturers. Jon was appointed Chief Executive Officer in June 2016.



Daniel Coatsworth

Daniel Coatsworth, Editor - Shares


Daniel Coatsworth is the editor at Shares and has written for the publication since 2005. He previously wrote for Teletext about the UK stock market and money matters, and his work has also appeared in many of the UK's leading newspapers, news websites and personal finance magazines. He is an expert on equities and funds and is also one of the leading commentators in the field of financial education for the retail investment market.

Steven Cooklin

Steven Cooklin, CEO - Manolete (MANO)


Steven Cooklin founded Manolete Partners in 2009 and is Chief Executive. Steven is a Chartered Accountant having qualified at Coopers and Lybrand in 1991. Steven has over 20 years’ experience in corporate finance with National Westminster Bank, Calder Corporate Advisory Ltd and Hill Samuel Investment Bank and is a former director of HSBC Investment Bank (Corporate Finance Division). Steven is an Associate Member of The Association of Business Recovery Professionals.

Nick Dashwood Brown

Nick Dashwood Brown, Head of Investor Relations - Anexo Group (ANX)


Nick has over 25 years’ experience in the investment industry. Initially covering South-East Asia, he changed focus to the UK in 1998 and has held senior roles in equity sales, trading and corporate broking. He joined Anexo Group in May 2019 as their first dedicated investor relations representative.

Nick has an MA in Mediaeval History from the University of St Andrews. He also attended the College of Law and was articled as a solicitor at Clifford Chance.

Cathal Friel

Cathal Friel, Executive Chairman - Open Orphan (ORPH)


Cathal is Executive Chairman at Open Orphan plc which is creating a rapidly growing European full pharmaceutical services company with a platform of complementary specialised service providers. Cathal co-founded Open Orphan in 2017, in June 2019 Open Orphan completed its reverse takeover of Venn Life Sciences and in January 2020 completed a merger with hVIVO plc. Prior to establishing Raglan Capital, Cathal was a co-founder and Director of Merrion Stockbrokers in 2000 which was successfully sold for €80m in 2006.

Stuart Gall

Stuart Gall, CEO - Intelligent Ultrasound Group (MED)


Stuart was appointed CEO of Intelligent Ultrasound in 2009. He was a joint founder and executive director of Fusion IP, an AIM-listed university IP commercialisation company, before its purchase by IP Group for £103 million in 2014. Stuart has a sales, marketing and general management background with over 25 years’ experience in starting small technology led companies, fund raising for and managing SMEs and acting as an executive director for several public companies. He has previously worked at British Airways, the Promotions Partnership, Anvil and Toad Group.


Professor Christopher Hancock

Professor Christopher Hancock, Founder & CTO - Creo Medical Group (CREO)


Chris is the founder of Creo Medical with over 20 years’ experience in medical device innovation and development. He holds a personal Chair in the Medical Microwave Systems Research Group at Bangor University. Chris is a Fellow of the Institute of Physics, a Chartered Physicist, Fellow of the Institute of Engineering and Technology, a Chartered Engineer and a Senior Member of the IEEE. He is also a Royal Academy of Engineering Visiting Professor at UCL and was awarded Katherine Burr Blodgett Gold Medal and Prize in 2018 for work on the Creo Medical Platform Technology. Chris is a named inventor and lead author on over 800 granted patents, patent applications and international journal publications.

James Hickman

James Hickman, CCO - Equals Group (EQLS)


James has over 20 years’ experience in currency markets and has set up several successful currency card programmes and a leading online money transfer platform.

Matthew Hudson

Matthew Hudson, CEO - MJ Hudson (MJH)


Matthew Hudson is CEO of MJ Hudson. Matthew has over 30 years of asset management experience, both as a lawyer and as an investor. Matthew has created and led major UK and US law firms in asset management law, as well as spending a number of years in large investment groups, before creating his own consultancy, MJ Hudson, from scratch in 2010. Matthew also wrote two leading text books in the asset management industry, both published by Wiley Finance.

Neil Johnson

Neil Johnson, CEO - Duke Royalty (DUKE)


Neil Johnson is Duke Royalty’s founder and CEO.  Mr. Johnson has 25 years of experience in investment banking and fund management in the Canadian and UK capital markets. During his 19 years at Canaccord Genuity, he was Head of Corporate Finance for 7 years in London and raised over £3 billion for Canadian dual-listed companies, and Canaccord became AIM’s #1 Broker.

Philip Johnston

Philip Johnston, CEO - Trackwise Designs (TWD)


Philip’s early career was in the space industry which included a key project management role in the Prime Contractor team for Envisat, a major European satellite programme. Philip joined Trackwise in 1999 and acquired the Company in 2000. Under his stewardship the Company has enjoyed sustained growth based largely through export success and innovation. Philip is named inventor on a number of UK and international patents.

Philip holds degrees in both Aeronautical Engineering and Law and is a Chartered Engineer.

Peter Keeling

Peter Keeling, CEO - Diaceutics (DXRX)


As CEO of Diaceutics, Peter Keeling’s role with the company complements over thirty years’ experience in international healthcare which began at GSK and Diagnology. He has operated and led companies and teams in the US, Europe, Asia and BRIC countries, inspiring product innovation and global launches while repeatedly delivering high corporate value growth for shareholders. Widely published in peer reviewed economic and precision medicine journals; Peter is a seasoned speaker and is considered one of the world’s thought leaders in the diagnostic commercialization industry.

Mark Lawrence

Mark Lawrence, CEO - TClarke (CTO)


Mark has had 34 years with the company and started his career here by completing an electrical apprenticeship in 1987. He progressed through the company, becoming Technical Director in 1997, Executive Director in 2003 and Managing Director, London Operations in 2007. As Group Chief Executive Officer since January 2010, Mark has led strategic changes across the group and remains a hands-on leader, taking personal accountability and pride in TClarke's performance and, ultimately our shareholders’ and clients’ satisfaction.


Trevor Mitchell

Trevor Mitchell, Finance Director - TClarke (CTO)


Trevor was appointed to the Board in February 2018. He is a Chartered Accountant and an accomplished finance professional with extensive experience across many sectors, including financial services, construction and maintenance, education and retail.


Julian Morse

Julian Morse, Head of Growth Companies - Cenkos Securities


Julian is Head of the Growth Companies Team and one of the founding members of Cenkos, as well as being appointed as an executive board member of Cenkos Securities plc. He has over 22 years’ experience in the City, and he has been involved in 100s of successful fund raisings and IPOs. Previously, Julian was a Director at Beeson Gregory and Evolution Securities.


Richard Penny

Richard Penny, Fund Manager - CRUX Asset Management


Richard joined CRUX Asset Management in June 2018 from Legal & General Investment Management. Richard is Fund Manager of the FP CRUX UK Special Situations Fund since it launched in October 2018. Richard had worked at LGIM for 15 years where he had managed the award-winning L&G UK Alpha Trust and L&G UK Special Situations Trust as well as several segregated mandates. Richard has a master’s degree in Engineering and Economics from Oxford University.

Matthew Sassone

Matthew Sassone, CEO - LiDCO (LID)


Matt Sassone took over the role of Chief Executive Officer during August 2015 following the retirement the business’ founder Dr Terry O’Brien. He has over 20 years’ experience in the medical industry having started his career in sales for Quintiles in 1996. He spent 12 years at Smiths Medical in various sales, marketing and

business development roles achieving the role of Regional Managing Director, Northern and Eastern Europe and Russia in 2010. In 2012 he moved to ArjoHuntleigh, a division of the Getinge Group, as Senior Vice President Global Marketing and was subsequently appointed Chief Marketing Officer of Maquet, also a division of

Getinge. Matt Sassone has a degree in biochemistry with microbiology.


Sean Smith

Sean Smith, CEO - Eden Research (EDEN)


Sean has a bachelors degree in microbiology and over 25 years of experience in the speciality chemicals and industrial biotechnology industries. He has held senior commercial leadership roles ranging from sales and marketing to business management and intellectual property licensing in blue chip companies such as Ciba (now BASF) and Honeywell. In recent years, Sean has focussed on technology commercialization through licensing and company formation working with Intellectual Ventures and several start-ups.


Roland Spencer

Roland Spencer, Head of Sales - Shares


Roland is Head of Sales at AJ Bell Media and has responsibility for sponsorship and advertising across their portfolio of investor engagement events, awards, websites and Shares magazine having joined the publication in 2008. Roland started his career in financial media in 2000 and has experience in the hedge fund, institutional investment and pensions and retirement sectors.

Dmitri Tsvetkov

Dmitri Tsvetkov, CFO, Director - OPG Power Ventures (OPG)


Mr Tsvetkov has over 25 years of financial, accounting and operational experience, including significant experience of working with promoter/founder-led energy sector listed companies in London, Africa, Asia and Canada. Mr Tsvetkov was Chief Financial Officer of OPG Power Generation Pvt Ltd, the Chennai subsidiary of OPG from July 2017 to October 2017.He has a Chartered Accountant (CA) designation from the Canadian Institute of Chartered Accountants, an FCCA designation from the Association of Chartered and Certified Accountants in the UK and Chartered Financial Analyst (CFA) designation from the CFA Institute in the US.

Tim Watts

Tim Watts, CFO - Shield Therapeutics (STX)


Tim joined Shield Therapeutics as Interim Chief Financial Officer in August 2018 and has over 25 years’ experience in the pharmaceutical and biotech sectors. A qualified chartered accountant, Tim was at AstraZeneca for 22 years, and was Group Financial Controller of AstraZeneca from 2002 to 2006. Between 2007 and 2011 Tim was CFO of Archimedes Pharma and CFO of Oxford Biomedica plc from 2012 until September 2017. Tim is also a non-executive director of Fusion Antibodies plc.


Gervais Williams

Gervais Williams, Senior Executive Director - Miton Group


Gervais Williams joined Miton Group plc in 2011. He manages a number of funds and trusts that aggregate to a little under £2.0bn. His fund management career extends over 30 years including 17 years at Gartmore. Gervais is a member of the AIM Advisory Council, chairman of the Quoted Companies Alliance and a board member of The Investment Association. He has written three books 'Slow Finance'; 'The Future is Small'; and his most recent book 'The Retreat of Globalisation.

Jenny Winter

Jenny Winter, CEO - Animalcare Group (ANCR)


Jenny spent most of her career in Human Pharmaceuticals with GSK and AstraZeneca and worked in a range of roles including Research and Development, Sales, Marketing, General Management, Product development, Corporate Affairs and Supply chain.  Jenny also spent some time as CEO of a charity for children with cancer and was a Non-Executive Director of Allied Irish Bank and the Project Management Group.

Jenny joined Animalcare in October 2018 as CEO.

Shaun Yates

Shaun Yates, Head of Investor Relations - AJ Bell (AJB)


Shaun joined AJ Bell in 2010, having trained as an accountant in a public practice based in Lancashire. He was appointed as Head of Investor Relations in March 2018, ahead of AJ Bell plc's listing on the main market of the London Stock Exchange in December 2018.

Shaun is a fellow member of the Association of Chartered Certified Accountants and a member of the Investor Relations Society.

Register Now